Imaging & Dosimetry
See the target. Measure where the radiation goes – “What you see is what you treat”
Molecular imaging is not only a diagnostic tool. In radiopharmaceutical development, it can provide direct information about target expression, biodistribution and radiation dose.
uTRACE® PET imaging
Non-invasive visualization of uPAR
uTRACE® PET imaging enables non-invasive visualization of uPAR in tumors. Across the clinical program, uPAR PET has been used to characterize uptake in primary tumors and metastases and to investigate relationships between uptake, tumor biology and clinical outcomes.
For therapy
Dosimetry
For therapy, quantitative imaging supports dosimetry: estimating the radiation absorbed by tumor and normal organs. This is central to Curasight’s development approach because the objective is not simply to deliver radioactivity, but to understand whether sufficient radiation can be delivered to tumor while respecting normal-organ dose constraints.
Glioblastoma Phase 1
In the ongoing glioblastoma Phase 1 study within uTREAT®, 64Cu-DOTA-AE105 is administered for imaging and dosimetry to evaluate tumor delivery, biodistribution, retention and organ exposure following local administration.
The purpose is to generate human delivery and dosimetry data that can inform subsequent therapeutic dosing with a separate 177Lu product.
Learn more
Science
Radiation delivered by a targeting molecule
Pipeline
uTRACE® is Curasight’s uPAR-targeted imaging and diagnostic platform.
Clinical evidence
A clinical program spanning imaging, prognosis, diagnosis and the first human delivery and dosimetry study supporting therapeutic development.